These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15952536)

  • 1. [3-year results of clinical and immunological monitoring of patients with multiple sclerosis treated by copaxone].
    Orlova IuIu; Alifirova VM; Cherdyntseva NV; Zagrebina IA; Bychkova IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(5):23-7. PubMed ID: 15952536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
    Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
    Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
    Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
    J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study.
    Farina C; Wagenpfeil S; Hohlfeld R
    J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
    Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS
    Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunogenetic cytokine restriction in multiple sclerosis].
    Odinak MM; Bisaga GN; kalinina NM; Akimov SB; Davydova NI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(9):39-44. PubMed ID: 11586702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis].
    Petrova LV; Boĭko AN; Batysheva TT; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):41-5. PubMed ID: 21311486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.
    Miller A; Shapiro S; Gershtein R; Kinarty A; Rawashdeh H; Honigman S; Lahat N
    J Neuroimmunol; 1998 Dec; 92(1-2):113-21. PubMed ID: 9916886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
    Demina TL; Davydovskaia MV; Lashch NIu; Popova NF; Khachanova NV; Zhuchenko TD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):91-7. PubMed ID: 12938642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate.
    Rieks M; Hoffmann V; Aktas O; Juschka M; Spitzer I; Brune N; Schimrigk S; Przuntek H; Pöhlau D
    Eur Neurol; 2003; 50(4):200-6. PubMed ID: 14634263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy].
    Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Ovcharov VV; Popova NF; Sinbukhova NI; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():101-10. PubMed ID: 17172244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.
    Ross CJ; Towfic F; Shankar J; Laifenfeld D; Thoma M; Davis M; Weiner B; Kusko R; Zeskind B; Knappertz V; Grossman I; Hayden MR
    Genome Med; 2017 May; 9(1):50. PubMed ID: 28569182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate (Copaxone).
    Francis DA
    Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].
    Boĭko AN; Davydovskaia MV; Demina TL; Lashch NIu; Ovcharov VV; Popova EV; Popova NF; Romashkin AV; Boĭko OV; Khachanova NV; Sharanova SN; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):86-92. PubMed ID: 22677683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of glatiramer acetate in clinical practice: an observational study.
    Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
    Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.
    Charach G; Grosskopf I; Weintraub M
    Digestion; 2008; 77(3-4):198-200. PubMed ID: 18607107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood cell immunomarkers in the course of methylprednisolone treatment of multiple sclerosis relapses.
    Michałowska-Wender G; Wender M
    Folia Neuropathol; 2008; 46(2):134-8. PubMed ID: 18587707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.